304 related articles for article (PubMed ID: 33586045)
1. Incidence of chemotherapy-induced nausea and vomiting among cancer patients receiving moderately to highly emetogenic chemotherapy in cancer centers in Sichuan, China.
Sun Y; Zheng Y; Yang X; Xie K; Du C; He L; Gui Y; Fu J; Li C; Zhang H; Zhu L; Bie J; Sun Y; Fu Y; Zhou Y; Shou F; Wang Y; Zhu J
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2701-2708. PubMed ID: 33586045
[TBL] [Abstract][Full Text] [Related]
2. Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy.
Hu Z; Liang W; Yang Y; Keefe D; Ma Y; Zhao Y; Xue C; Huang Y; Zhao H; Chen L; Chan A; Zhang L
Medicine (Baltimore); 2016 Jan; 95(2):e2476. PubMed ID: 26765450
[TBL] [Abstract][Full Text] [Related]
3. Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes.
Liau CT; Chu NM; Liu HE; Deuson R; Lien J; Chen JS
Support Care Cancer; 2005 May; 13(5):277-86. PubMed ID: 15770489
[TBL] [Abstract][Full Text] [Related]
4. Adherence to pediatric acute chemotherapy-induced nausea and vomiting guidelines in Canadian hospitals.
McKinnon K; Jupp J; Ghosh S; Digout C; Eason S; Romanick M
Pediatr Blood Cancer; 2019 Jan; 66(1):e27488. PubMed ID: 30318842
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan.
Baba Y; Baba H; Yamamoto S; Shimada H; Shibata T; Miyazaki T; Yoshikawa T; Nakajima Y; Tsuji Y; Shimokawa M; Kitagawa Y; Aiba K
Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 27001532
[TBL] [Abstract][Full Text] [Related]
6. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study.
Molassiotis A; Aapro M; Dicato M; Gascon P; Novoa SA; Isambert N; Burke TA; Gu A; Roila F
J Pain Symptom Manage; 2014 May; 47(5):839-848.e4. PubMed ID: 24075401
[TBL] [Abstract][Full Text] [Related]
8. The incidence of nausea in the absence of vomiting in patients receiving intravenous chemotherapy.
Smit T; Kotze I; du Plessis J
Ann Palliat Med; 2021 Mar; 10(3):2679-2686. PubMed ID: 33549001
[TBL] [Abstract][Full Text] [Related]
9. Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries.
Hsieh RK; Chan A; Kim HK; Yu S; Kim JG; Lee MA; Dalén J; Jung H; Liu YP; Burke TA; Keefe DM
Support Care Cancer; 2015 Jan; 23(1):263-72. PubMed ID: 25120009
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study.
Hilarius DL; Kloeg PH; van der Wall E; van den Heuvel JJ; Gundy CM; Aaronson NK
Support Care Cancer; 2012 Jan; 20(1):107-17. PubMed ID: 21258948
[TBL] [Abstract][Full Text] [Related]
11. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
Shih V; Wan HS; Chan A
Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance).
Kottschade L; Novotny P; Lyss A; Mazurczak M; Loprinzi C; Barton D
Support Care Cancer; 2016 Jun; 24(6):2661-7. PubMed ID: 26768436
[TBL] [Abstract][Full Text] [Related]
13. Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study.
Escobar Y; Cajaraville G; Virizuela JA; Álvarez R; Muñoz A; Olariaga O; Tamés MJ; Muros B; Lecumberri MJ; Feliu J; Martínez P; Adansa JC; Martínez MJ; López R; Blasco A; Gascón P; Calvo V; Luna P; Montalar J; Del Barrio P; Tornamira MV
Support Care Cancer; 2015 Sep; 23(9):2833-40. PubMed ID: 26081597
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)-a systematic review and individual patient data meta-analysis.
Chow R; Yin LB; Baqri W; Huang R; Boldt G; Younus J; Lock M; Prsic E; Zimmermann C; Herrstedt J
Support Care Cancer; 2023 Aug; 31(8):505. PubMed ID: 37535218
[TBL] [Abstract][Full Text] [Related]
15. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
Lindley C; Goodin S; McCune J; Kane M; Amamoo MA; Shord S; Pham T; Yowell S; Laliberte K; Schell M; Bernard S; Socinski MA
Am J Clin Oncol; 2005 Jun; 28(3):270-6. PubMed ID: 15923800
[TBL] [Abstract][Full Text] [Related]
16. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of antiemetic in reducing chemotherapy-induced nausea and vomiting in adult patients; An oncology center experience.
Al-Salloum HF; Al-Harbi HE; Abdelazeem A
J Oncol Pharm Pract; 2023 Sep; 29(6):1317-1325. PubMed ID: 36518002
[TBL] [Abstract][Full Text] [Related]
18. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparative Study From Sudan.
Osman AAM; Elhassan MMA; AbdElrahim BHA; Ahmed FHA; Yousif JBH; Ahmed MAM; Abdelhafeez RHA; Ahmed UMY
J Glob Oncol; 2018 Sep; 4():1-9. PubMed ID: 30241275
[TBL] [Abstract][Full Text] [Related]
19. The cost of antiemetic therapy for chemotherapy-induced nausea and vomiting in patients receiving platinum-containing regimens in daily practice in Japan: a retrospective study.
Hamada S; Hinotsu S; Hori K; Furuse H; Oikawa T; Kawakami J; Ozono S; Akaza H; Kawakami K
Support Care Cancer; 2012 Apr; 20(4):813-20. PubMed ID: 21472498
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.
Willier S; Cabanillas Stanchi KM; von Have M; Binder V; Blaeschke F; Feucht J; Feuchtinger T; Döring M
BMC Cancer; 2019 Nov; 19(1):1118. PubMed ID: 31730451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
